Omkar Pharmachem

Why is Omkar Pharmachem Ltd falling/rising?

As of 09-Jun, Omkar Pharmachem Ltd's stock price is at Rs. 21.27, down 4.96%, reflecting a significant decline over various periods and reaching a new 52-week low. The stock shows a bearish trend with increased selling pressure and underperformance compared to its sector.

As of 09-Jun, Omkar Pharmachem Ltd's stock price is falling, currently at Rs. 21.27, which represents a decrease of Rs. 1.11 or 4.96%. This decline is part of a broader trend, as the stock has underperformed significantly over various periods, with a 1-week drop of 17.08% and a 1-month decline of 24.12%. Additionally, the stock has reached a new 52-week low today, indicating a lack of investor confidence.<BR><BR>The stock has been on a consecutive downward trajectory for the last two days, accumulating a total loss of 9.68% during this period. Today's performance has also seen it underperform its sector by 5.77%. The trading volume indicates that more transactions occurred closer to the lower price, suggesting that investors are selling off shares rather than buying.<BR><BR>Moreover, while the stock's moving averages are higher than the 200-day moving average, they remain lower than the 5-day, 20-day, 50-day, and 100-day moving averages, which could indicate a bearish trend. Despite a slight increase in delivery volume by 10.22% against the 5-day average, the overall sentiment appears negative, contributing to the stock's decline.

Which are the latest news on Omkar Pharmachem?

When is the next results date for Omkar Pharmachem Ltd?

The next results date for Omkar Pharmachem Ltd is 30 May 2026.

The next results date for Omkar Pharmachem Ltd is scheduled for 30 May 2026.

Is Omkar Pharmachem overvalued or undervalued?

As of August 12, 2025, Omkar Pharmachem is considered very expensive and overvalued, with a PE ratio of 25.90 and a PEG ratio of 4.92, indicating its growth prospects do not justify its current price despite a strong historical return of 323.06%.

As of 12 August 2025, the valuation grade for Omkar Pharmachem has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 25.90, an EV to EBIT ratio of 26.13, and a ROCE of only 3.17%, which raises concerns about its profitability relative to its valuation.<BR><BR>In comparison to its peers, Omkar Pharmachem's valuation metrics appear less favorable. For instance, Sun Pharma has a PE ratio of 33.93, while Cipla offers a more attractive PE of 22.77. Additionally, the PEG ratio of 4.92 suggests that the company's growth prospects may not justify its current price. Despite a strong historical performance over the last decade, with a return of 323.06%, the current valuation does not align with its financial fundamentals, reinforcing the conclusion that Omkar Pharmachem is overvalued.

How has been the historical performance of Omkar Pharmachem?

Omkar Pharmachem has shown minimal financial activity, with net sales at zero since Mar'18, but has stabilized other operating income at 0.54 Cr since Mar'22. While profit metrics have gradually improved, the company still carries negative reserves, though the deficit has decreased from -1.42 Cr in Mar'21 to -0.65 Cr in Mar'25.

Answer:<BR>The historical performance of Omkar Pharmachem shows a consistent trend of minimal financial activity over the years, with net sales remaining at zero from Mar'18 to Mar'25. The company has reported other operating income of 0.54 Cr for Mar'24 and Mar'25, which is an increase from 0.27 Cr in Mar'21. Total operating income has remained stable at 0.54 Cr since Mar'22. The total expenditure, excluding depreciation, has varied slightly, with a peak of 0.27 Cr in Mar'22 and a low of 0.23 Cr in Mar'23, leading to an operating profit (PBDIT) that has fluctuated around 0.29 Cr to 0.31 Cr in recent years. Profit before tax has shown a gradual improvement, reaching 0.27 Cr in Mar'25, while profit after tax has also increased slightly to 0.20 Cr in the same period. The company has maintained a negative reserve balance, which has improved from -1.42 Cr in Mar'21 to -0.65 Cr in Mar'25. <BR><BR>Breakdown:<BR>Omkar Pharmachem's financial performance indicates a lack of significant revenue generation, with net sales consistently reported as zero over the past several years. The company has, however, managed to generate some other operating income, which has stabilized at 0.54 Cr since Mar'22, reflecting a modest increase from previous years. Total expenditure has remained relatively low, allowing for a positive operating profit that has hovered around 0.29 Cr to 0.31 Cr in the last few years. Profit before tax has shown a positive trend, reaching 0.27 Cr in Mar'25, while profit after tax has also seen slight growth, indicating some operational stability. Despite these improvements, the company continues to carry negative reserves, although there has been a gradual reduction in the deficit over the years, suggesting a potential for future recovery. Overall, the financial data reflects a company that has not yet achieved significant operational success but is showing signs of gradual improvement in profitability metrics.

What is the technical trend for Omkar Pharmachem?

As of May 12, 2025, Omkar Pharmachem shows a mildly bullish trend, supported by daily moving averages and Bollinger Bands, though caution is advised due to bearish signals from the weekly and monthly MACD and RSI.

As of 12 May 2025, the technical trend for Omkar Pharmachem has changed from does not qualify to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly and monthly MACD and RSI readings are mildly bearish. However, the Bollinger Bands are showing a mildly bullish trend on both weekly and monthly time frames. The KST is bullish on both weekly and monthly, which adds some strength to the mildly bullish outlook. Overall, the current stance is mildly bullish, but caution is advised due to the bearish signals from the MACD and RSI on the weekly and monthly charts.

how big is Omkar Pharmachem?

As of Jun 06, Omkar Pharmachem Ltd has a market capitalization of 28.00 Cr, classifying it as a Micro Cap company, with total assets of 9.49 Cr and shareholder's funds of 9.23 Cr as of Mar'24. The company reported net sales of 0.00 Cr and a net profit of 0.20 Cr over the latest four quarters.

Market Cap: As of Jun 06, Omkar Pharmachem Ltd has a market capitalization of 28.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 0.00 Cr. The sum of Net Profit for the same quarters is 0.20 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period ending in Mar'24. Shareholder's Funds are valued at 9.23 Cr, and Total Assets amount to 9.49 Cr.

Who are the top shareholders of the Omkar Pharmachem?

The top shareholders of Omkar Pharmachem include promoter Shah Kirtikumar Laxmichand with 0.02% and public shareholder Kuldeep Singh with 3.72%. Individual investors hold a significant 98.36% of the shares, with no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Omkar Pharmachem include Shah Kirtikumar Laxmichand, who is the promoter with the highest holding at 0.02%. The highest public shareholder is Kuldeep Singh, holding 3.72%. Additionally, individual investors collectively hold a significant portion, accounting for 98.36% of the shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares.

What does Omkar Pharmachem do?

Omkar Pharmachem Ltd is a micro-cap company focused on pharmaceuticals and chemical products, primarily providing support services. As of March 2025, it reported a net profit of 0 Cr and has a market cap of Rs 28 Cr.

Overview: <BR>Omkar Pharmachem Ltd is engaged in the business of pharmaceuticals and chemical products within the commodity chemicals industry, classified as a micro-cap company.<BR><BR>History: <BR>The company was incorporated on 31 March 1995. It has not conducted any commercial activity during the year and is currently focused on providing support services related to pharmaceuticals and chemicals. The latest quarterly results reported net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 28 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 28.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.02 <BR>Return on Equity: 2.17% <BR>Price-to-Book: 3.04 <BR><BR>Contact Details: <BR>Address: 501 Mahakant Bldg Ashram Road, Opp V S Hospital Ellisbridge Ahmedabad Gujarat : 380006 <BR>Tel: 91-079-26580892 <BR>Email: investors.opl@gmail.com <BR>Website: http://www.omkarpharmachem.co.in

Who are in the management team of Omkar Pharmachem?

As of March 2018, the management team of Omkar Pharmachem includes Anurag Sharma (Managing Director), Parminder Sharma (Non Executive Director), Mamta Pachori (Non Executive Independent Director), Janak Raj (Non Executive Independent Director), and Pankaj Singh (Company Secretary & Compliance Officer).

As of March 2018, the management team of Omkar Pharmachem consists of the following individuals:<BR><BR>1. Anurag Sharma - Managing Director<BR>2. Parminder Sharma - Non Executive Director<BR>3. Mamta Pachori - Non Executive Independent Director<BR>4. Janak Raj - Non Executive Independent Director<BR>5. Pankaj Singh - Company Secretary & Compliance Officer<BR><BR>These members play various roles in the governance and operational oversight of the company.

Has Omkar Pharmachem declared dividend?

No Dividend History Available

Who are the peers of the Omkar Pharmachem?

Omkar Pharmachem's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Hind.Fluoro Carb, Pentokey Organy, Jayshree Chem., and Sreechem Resins. Key insights show varying management risks, growth rates, and capital structures among these peers, with India Glycols leading in 1-year returns at 150.39% and Hind.Fluoro Carb at -23.85%.

Peers: The peers of Omkar Pharmachem are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Hind.Fluoro Carb, Pentokey Organy, Jayshree Chem., and Sreechem Resins.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Sreechem Resins, while Good management risk is found at Chemplast Sanmar and the rest. Average management risk is noted for Tata Chemicals and India Glycols, while Below Average management risk is present at Fischer Medical, Pentokey Organy, and Jayshree Chem. The remaining peers, Hind.Fluoro Carb and Omkar Pharmachem, do not qualify. Growth is below average for Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Hind.Fluoro Carb, Pentokey Organy, and Jayshree Chem., while average growth is seen at Fischer Medical, and Sreechem Resins has good growth. Omkar Pharmachem does not qualify for growth. Capital structure is excellent at GHCL, average at Tata Chemicals and Sreechem Resins, and below average at Chemplast Sanmar, India Glycols, Fischer Medical, Pentokey Organy, and Jayshree Chem., with Hind.Fluoro Carb and Omkar Pharmachem not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is India Glycols at 150.39%, while the lowest is Hind.Fluoro Carb at -23.85%. Omkar Pharmachem's 1-year return is 26.92%, which is positive compared to Hind.Fluoro Carb but lower than India Glycols. Additionally, the peers with negative six-month returns include Tata Chemicals, Chemplast Sanmar, Hind.Fluoro Carb, and Sreechem Resins.